300 related articles for article (PubMed ID: 16169315)
21. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
[TBL] [Abstract][Full Text] [Related]
22. Aspiration thrombectomy during primary percutaneous coronary intervention as adjunctive therapy to early (in-ambulance) abciximab administration in patients with acute ST elevation myocardial infarction: an analysis from Leiden MISSION! acute myocardial infarction treatment optimization program.
Ahmed TA; Atary JZ; Wolterbeek R; Hasan-Ali H; Abdel-Kader SS; Schalij MJ; Jukema JW
J Interv Cardiol; 2012 Feb; 25(1):1-9. PubMed ID: 22059390
[TBL] [Abstract][Full Text] [Related]
23. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
[TBL] [Abstract][Full Text] [Related]
24. Heart-type fatty acid binding protein--a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation.
Figiel Ł; Kasprzak JD; Peruga J; Lipiec P; Drozdz J; Krzemińska-Pakuła M; Smigielski J
Kardiol Pol; 2008 Mar; 66(3):253-9, discussion 260-1. PubMed ID: 18393112
[TBL] [Abstract][Full Text] [Related]
25. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
26. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
Danzi GB; Sesana M; Capuano C; Mauri L; Predolini S; Baglini R
Int J Cardiol; 2006 Feb; 107(2):241-6. PubMed ID: 16412804
[TBL] [Abstract][Full Text] [Related]
27. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
28. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
[TBL] [Abstract][Full Text] [Related]
29. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).
Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL;
Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147
[TBL] [Abstract][Full Text] [Related]
30. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
[TBL] [Abstract][Full Text] [Related]
31. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Ulm K; Berger PB; Schömig A
Circulation; 2006 Nov; 114(19):2040-6. PubMed ID: 17060377
[TBL] [Abstract][Full Text] [Related]
32. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
[TBL] [Abstract][Full Text] [Related]
33. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
34. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
[TBL] [Abstract][Full Text] [Related]
35. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
Registro Osservazionale Angina Instabile Investigators
Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
[TBL] [Abstract][Full Text] [Related]
36. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
37. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
38. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
Galla JM; Mahaffey KW; Sapp SK; Alexander JH; Roe MT; Ohman EM; Granger CB; Armstrong PW; Harrington RA; White HD; Simoons ML; Newby LK; Califf RM; Topol EJ
Am Heart J; 2006 Jan; 151(1):16-24. PubMed ID: 16368286
[TBL] [Abstract][Full Text] [Related]
39. Differential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practice.
Gowda MS; Vacek JL; Lakkireddy DJ; Brosnahan K; Beauchamp GD
Angiology; 2003; 54(2):211-8. PubMed ID: 12678197
[TBL] [Abstract][Full Text] [Related]
40. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.
Yan HB; Li SY; Song L; Wang J; Wu Z; Chi YP; Zheng B; Zhao HJ; Li QX; Zhang XJ; Li WZ
Chin Med J (Engl); 2010 Apr; 123(7):877-83. PubMed ID: 20497681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
